北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer
作者: Bai, Hua; Mao, Li; Wang, Hang Shu; Zhao, Jun; Yang, Lu; An, Tong Tong; Wang, Xin; Duan, Chun Jian; Wu, Na Mei; Guo, Zhi Qing; Liu, Yi Xu; Liu, Hong Ning; Wang, Ye Yu; Wang, Jie1
刊名: JOURNAL OF CLINICAL ONCOLOGY
发表日期: 2009-06-01
DOI: 10.1200/JCO.2008.17.3930
卷: 27, 期:16, 页:2653-2659
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: PREVIOUSLY TREATED PATIENTS ; SERUM DNA ; TYROSINE KINASE ; GENE-MUTATIONS ; GEFITINIB ; TRIAL ; COMBINATION ; INHIBITOR ; ERLOTINIB ; IRESSA
英文摘要:

Purpose

Mutations in the epidermal growth factor receptor ( EGFR) kinase domain can predict tumor response to tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). However, obtaining tumor tissues for mutation analysis is challenging. We hypothesized that plasma-based EGFR mutation analysis is feasible and has value in predicting tumor response in patients with NSCLC.

Patients and Methods

Plasma DNA samples and matched tumors from 230 patients with stages IIIB to IV NSCLC were analyzed for EGFR mutations in exons 19 and 21 by using denaturing high-performance liquid chromatography. We compared the mutations in the plasma samples and the matched tumors and determined an association between EGFR mutation status and the patients′ clinical outcomes prospectively.

Results

In 230 patients, we detected 81 EGFR mutations in 79 (34.3%) of the patients′ plasma samples. We detected the same mutations in 63 (79.7%) of the matched tumors. Sixteen plasma (7.0%) and fourteen tumor (6.1%) samples showed unique mutations. The mutation frequencies were significantly higher in never-smokers and in patients with adenocarcinomas (P=.012 and P=.009, respectively). In the 102 patients who failed platinum-based treatment and who were treated with gefitinib, 22 (59.5%) of the 37 with EGFR mutations in the plasma samples, whereas only 15 (23.1%) of the 65 without EGFR mutations, achieved an objective response (P=.002). Patients with EGFR mutations had a significantly longer progression-free survival time than those without mutations (P=.044) in plasma.

Conclusion EGFR mutations can be reliably detected in plasma DNA of patients with stages IIIB to IV NSCLC and can be used as a biomarker to predict tumor response to TKIs. J Clin Oncol 27:2653-2659. (C) 2009 by American Society of Clinical Oncology

语种: 英语
WOS记录号: WOS:000266454600015
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/62982
Appears in Collections:北京大学临床肿瘤学院_胸部肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Sch Oncol, Dept Thorac Med Oncol, Beijing Canc Hosp & Inst, Beijing 100036, Peoples R China
2.Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

Recommended Citation:
Bai, Hua,Mao, Li,Wang, Hang Shu,et al. Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer[J]. JOURNAL OF CLINICAL ONCOLOGY,2009,27(16):2653-2659.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Bai, Hua]'s Articles
[Mao, Li]'s Articles
[Wang, Hang Shu]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Bai, Hua]‘s Articles
[Mao, Li]‘s Articles
[Wang, Hang Shu]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace